Faeth Therapeutics grants director 25,000 stock options

The 25,000 options vest in 36 equal monthly installments, subject to continuous service through each vesting date.

Rhea-AI Filing Summary

Faeth Therapeutics, Inc. director Adam Schayowitz received a grant of stock options covering 25,000 common shares on October 23, 2026, with an exercise price of $17.08 per share and an expiration date of October 22, 2036. The options vest in 36 equal monthly installments over three years, becoming fully vested on October 23, 2029, subject to his continuous service on each vesting date.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider Schayowitz Adam

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	25,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 25,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or October 23, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Key Figures

Options granted: 25,000 options covering common shares Exercise price: $17.08 per share Vesting installments: 36 equal monthly installments +3 more

6 metrics

Options granted 25,000 options covering common shares Granted October 23, 2026

Exercise price $17.08 per share For the stock options

Vesting installments 36 equal monthly installments Over three years

Vesting period 3 years Options become fully vested on October 23, 2029, subject to continuous service

Full vesting date October 23, 2029 Subject to continuous service on each vesting date

Expiration date October 22, 2036 Stock options

Key Terms

Stock Option (right to buy), exercisable, continuous service

3 terms

Stock Option (right to buy) technical

"Stock Option (right to buy)"

exercisable technical

"vest and become exercisable in 36 equal monthly installments"

continuous service technical

"subject to the Reporting Person's continuous service with the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did FTH director Adam Schayowitz receive?

Adam Schayowitz, a Faeth Therapeutics director, received options covering 25,000 common shares on October 23, 2026, with an exercise price of $17.08 per share and an expiration date of October 22, 2036.

When do Adam Schayowitz’s FTH options vest?

The options vest in 36 equal monthly installments over three years and are fully vested on October 23, 2029, subject to Adam Schayowitz’s continuous service with Faeth Therapeutics on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/27/2026 - 04:17 PM EDT Accepted by SEC EDGAR 10/27/2026 - 04:17 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schayowitz Adam

(Last) (First) (Middle)

C/O FAETH THERAPEUTICS, INC.

701 TILLERY STREET #12 #1010

(Street)

AUSTIN TEXAS 78702

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Faeth Therapeutics, Inc. [ FTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$17.08	10/23/2026		A		25,000		(1)	10/22/2036	Common Stock	25,000	$0	25,000	D

Explanation of Responses:

1. The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or October 23, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

	/s/ Josiah Craver, Attorney-in-Fact	10/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)